规格: | 98% |
分子量: | 1002.23 |
包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
Background:
XY028-133 (example 14) is a PROTAC-based CDK4/6 degrader with anti-tumor activity[1].
XY028-133 (1 and 3 μM, 24 h) significantly decreases CDK4/6, Cyclin A, PLK1 and pRb protein levels in A375 cells[1].
[1]. JIN, Jian, et al. COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER. Patent. US2017/065027.